Beyond TP53 mutations, several molecular and clinical characteristics influence treatment intensification decisions. Dr. Rodriguez emphasizes that patient factors including age, comorbidities, and chemotherapy tolerance capacity must be considered alongside molecular features.
Both panelists acknowledge that most academic centers now adopt combination regimens as standard practice, with the TOP study providing additional supportive evidence rather than fundamentally changing treatment approaches. However, the data proves particularly valuable for clinicians who must prioritize resources or convince patients about combination therapy benefits.
Experts unpack TOP trial data on TP53 co-mutations, guiding first-line EGFR lung cancer choices between osimertinib alone or with chemo.
TOP study prospectively shows TP53-mutant EGFR lung cancer gains from first-line combination therapy, reshaping choices amid FLAURA2 and MARIPOSA.
Coral Olazagasti, MD, discusses the significance of providing resources to oncology physicians who are looking to strengthen their overall wellness.
Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.
Coral Olazagasti, MD discusses a tailored lung cancer screening program for Hispanic head and neck cancer survivors.
Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.
Outbreaks of coronavirus disease 2019 are on the rise in Latin America, with more than 4 million confirmed cases. In response to this health crisis, elective medical procedures, including cancer screening and care, as well as treatment for conditions beyond the virus, have been held.
